Belgian Media Stock News

ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Does Wells Fargo’s Q3 Tactical Pick Call Reframe argenx’s (ENXTBR:ARGX) Autoimmune Pipeline Narrative?

In late June 2026, Wells Fargo named argenx a top Q3 tactical pick, highlighting an upcoming clinical catalyst as a key focus for investors. This endorsement brings fresh attention to how argenx’s pipeline progress and near-term milestones could influence expectations for its autoimmune portfolio. We’ll now examine how Wells Fargo’s Q3 tactical pick call and the looming clinical catalyst feed into argenx’s existing investment narrative. The future of work is here. Discover the 29 top...
ENXTBR:ENRGY
ENXTBR:ENRGYElectrical

European Growth Stocks With High Insider Ownership June 2026

As European markets continue to navigate mixed macroeconomic data and geopolitical developments, the pan-European STOXX Europe 600 Index has shown resilience with a modest gain. In this context, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the business best.
ENXTBR:CMBT
ENXTBR:CMBTOil and Gas

Why Cmb.Tech (ENXTBR:CMBT) Is Up 6.8% After Securing Ammonia-Ready Fortescue Charter Deal – And What's Next

CMB.TECH NV announced that it has signed a milestone agreement with Fortescue for the charter of up to 12 ammonia-capable Newcastlemax vessels, including up to three dual-fuel ammonia ships expected to enter service by the end of 2026. The deal highlights CMB.TECH’s growing role in advancing ammonia as a marine fuel, with the potential to materially cut shipping emissions if powered by green ammonia. Next, we’ll examine how this large-scale ammonia-capable charter agreement with Fortescue...
ENXTBR:UCB
ENXTBR:UCBPharmaceuticals

Will Lupus PHOENYCS GO Data and Safety Overhaul Change UCB's (ENXTBR:UCB) Narrative

Earlier in June 2026, ELIQUENT Life Sciences announced that UCB went live with the full Veeva Safety Suite, consolidating its global pharmacovigilance operations into a single cloud-based platform delivered in collaboration with Veeva, Pinnaxis, and Daelight Solutions. Separately, UCB and Biogen presented Phase 3 PHOENYCS GO data at EULAR 2026 suggesting dapirolizumab pegol may help systemic lupus erythematosus patients sustain disease control while reducing long-term steroid exposure,...
ENXTBR:DIE
ENXTBR:DIERetail Distributors

A Look At D'Ieteren Group (ENXTBR:DIE) Valuation After Its Latest Dividend Announcement

Dividend announcement and what it means for investors D'Ieteren Group (ENXTBR:DIE) has declared an annual dividend of €1.40 per share, with an ex dividend date on 9 June 2026, record date on 10 June and payment on 11 June. This dividend decision puts income directly on the table for shareholders. It also offers a fresh data point on how management is choosing to return cash alongside the group’s investment focused business model. See our latest analysis for D'Ieteren Group. The dividend news...
ENXTBR:PROX
ENXTBR:PROXTelecom

Proximus Weighs Unifiber Deal As Valuation Gap And Risks Draw Focus

Proximus (ENXTBR:PROX) and Unifiber SA recently held an M&A call indicating interest in a potential transaction. The discussion signals that both companies are assessing options for closer collaboration or corporate action. Details on structure, timing, and financial terms have not been made public. For investors watching Proximus at a share price of €6.61, the prospect of an M&A move with Unifiber SA comes after a mixed share price record. The stock is down 7.6% year to date and down 44.3%...
ENXTBR:ACKB
ENXTBR:ACKBConstruction

Assessing Ackermans & Van Haaren (ENXTBR:ACKB) Valuation After Recent Share Price Softness

Recent performance snapshot for Ackermans & Van Haaren (ENXTBR:ACKB) Ackermans & Van Haaren (ENXTBR:ACKB) has drawn attention after a period where the stock is up 12.7% year to date, yet down 6.5% over the past month and 4.9% over the past 3 months. At a last close of €262.20 and a market value of about €8.57b, the company reports annual revenue of €5,961.61m and net income of €592.55m, with annual revenue growth of 2.18% and net income growth of 5.72%. See our latest analysis for Ackermans &...
ENXTBR:UMI
ENXTBR:UMIChemicals

Is It Time To Reassess Umicore (ENXTBR:UMI) After Its 178% One Year Surge?

Wondering if Umicore at €25.62 is offering genuine value or just catching your eye after a strong run? This article breaks down what the current price might be implying. The stock has recently returned 4.9% over 7 days, 50.2% over 30 days, 37.8% year to date, and 178.3% over 1 year, which naturally raises questions about how much of the story is already in the price. Recent coverage has focused on Umicore's position in materials and related technologies, with investors paying close attention...
ENXTBR:KBC
ENXTBR:KBCBanks

3 European Dividend Stocks To Consider With Up To 8% Yield

As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing by 3% amid hopes for geopolitical de-escalation, investors are increasingly seeking stable returns in an environment marked by adjusted growth forecasts and persistent inflation concerns. In such a climate, dividend stocks can offer an attractive option for generating income, as they provide regular payouts that can help offset market volatility and economic uncertainties.
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Is Syensqo (ENXTBR:SYENS) Refocusing Performance & Care to Strengthen Its Specialty Materials Identity?

In the first quarter of 2026, Syensqo reported sales of €1,461 million, with net income improving to €62 million from a small loss a year earlier, and basic earnings per share rising to €0.60. Ahead of these results, the company launched a review of its Performance & Care segment to sharpen its focus on specialty materials and advanced technologies across sectors such as aerospace, electronics, healthcare, energy, and advanced mobility. We’ll now consider how the Performance & Care segment...
ENXTBR:CMBT
ENXTBR:CMBTOil and Gas

Cmb.Tech (ENXTBR:CMBT) Q1 EPS Surge Tests Bearish Margin And Guidance Concerns

Cmb.Tech (ENXTBR:CMBT) opened 2026 with a busy quarter, reporting Q1 revenue of US$807.3 million and basic EPS of US$1.27, while trailing twelve month revenue sat at US$2.2 billion with EPS of US$1.92. This gives investors a fresh read on both quarterly momentum and the rolling earnings base behind the current €14.58 share price. Over recent periods the company has seen revenue move from US$235.0 million in Q1 2025 and US$226.0 million in Q4 2024 to US$807.3 million in Q1 2026, with basic EPS...
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Syensqo Share Cancellation Reshapes Ownership As Valuation Gap Persists

Syensqo cancelled a significant number of shares it had repurchased as part of its ongoing buyback program. The move changes the total number of outstanding shares and voting rights for ENXTBR:SYENS. The action forms part of a broader capital management approach that affects how ownership is distributed across shareholders. For investors watching ENXTBR:SYENS, the cancellation of repurchased shares directly alters the share count that sits behind the current €57.3 price. Recent performance...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Is It Time To Reassess argenx (ENXTBR:ARGX) After Its Strong Multi Year Run?

Investors may be wondering whether argenx at €678.60 is offering fair value or carrying a premium, particularly after its strong long term share price record. The stock has returned 2.0% over the last 7 days, 4.9% over the last 30 days, a 6.2% decline year to date and 19.8% over the last year, with longer term returns of 86.7% over 3 years and 220.1% over 5 years. Recent coverage around argenx has focused on its position in the biotech sector and investor debate around how much future growth...